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An Analysis of 112 Acute Porphyric Attacks
in Cape Town, South Africa
Evidence That Acute Intermittent Porphyria and Variegate
Porphyria Differ in Susceptibility and Severity
Richard J. Hift, PhD and Peter N. Meissner, PhD
Abstract: Four forms of porphyria may present clinically with the
acute attack, an episodic, severe, and potentially life-threatening
manifestation characterized by abdominal and neurologic symp-
toms. We describe our experience with 112 consecutive attacks
observed and treated in 25 patients with the 2 most common forms
of acute porphyria in Cape Town, South Africa; 25 attacks in 10
patients with variegate porphyria and 87 attacks in 14 patients with
acute intermittent porphyria. The remaining patient experienced
more than 100 sequential, severe, and poorly remitting attacks,
which are not included in our analysis. In our population, the rela-
tive risk of an acute attack in acute intermittent porphyria compared
with that in variegate porphyria was 14.3 (confidence intervals,
6.3–32.7). Patients with variegate porphyria were significantly
older (median age at first attack, 30 yr) than those with acute
intermittent porphyria (median age at first attack, 23.5 yr; p <
0.0001), and demonstrated an equal sex ratio, whereas the
male:female ratio in acute intermittent porphyria was 2:12 (p <
0.0001). There was a significant difference in the incidence of
factors precipitating the acute attack. Drug exposure was a frequent
precipitant of the acute attack in variegate porphyria, whereas
hormonal factors were more important in acute intermittent
porphyria (p < 0.00001). Patients with acute intermittent porphyria
also showed a trend to earlier and more frequent recurrent acute
attacks following the initial admission. Mean urine precursor levels,
blood pressure, pulse rate, and heme arginate requirement were all
significantly higher in patients with acute intermittent porphyria. No
significant difference in the frequency of serious complications or
in outcome could be shown. We describe our experience with
treatment with heme arginate, and provide evidence that heme
arginate results in a prompt and statistically significant improve-
ment in symptoms. The incidence of serious complications and
mortality in this series was low, confirming a trend to an
increasingly good prognosis for patients with acute porphyria who
receive expert treatment.
(Medicine 2005;84:48–60)
INTRODUCTION
T he porphyrias are a group of metabolic disordersassociated with enzyme defects in the heme synthetic
pathway and a consequent overproduction of porphyrins, the
essential intermediates of this pathway41. All are inherited,
although porphyria cutanea tarda may be acquired as a re-
sult of factors that may reversibly inhibit the enzyme
uroporphyrinogen decarboxylase22,23. Two of the porphyrias,
congenital erythropoietic porphyria and erythropoietic pro-
toporphyria, predominantly affect erythroid heme synthesis.
They may be diagnosed by demonstrating characteristic ele-
vations in porphyrin concentrations in erythrocytes. They
present clinically with photosensitivity, since porphyrins are
photoactive molecules, a property accounting for their char-
acteristic fluorescence under ultraviolet light39. Erythropoi-
etic protoporphyria may additionally be associated with
liver injury resulting from the hepatic uptake and accumu-
lation of protoporphyrin released from erythrocytes12.
The remaining porphyrias affect nonerythroid heme
synthesis and are described as ‘‘hepatic’’ porphyrias. In 3
porphyrias (porphyria cutanea tarda, hereditary copropor-
phyria, and variegate porphyria [VP]), porphyrins typically
accumulate in plasma and skin, resulting in a characteristic
photosensitivity. A second clinical presentation, the acute
neurovisceral crisis, also known as the acute attack, is seen
Abbreviations: AIP = acute intermittent porphyria, ALA = aminolevulinic
acid, CT = computed tomography, PBG = porphobilinogen, VP = variegate
porphyria.
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in patients with aminolevulinic acid (ALA) dehydratase defi-
ciency porphyria, acute intermittent porphyria (AIP), hered-
itary coproporphyria, and VP, which are collectively known
as ‘‘acute’’ porphyrias. The first of these is inherited as an
autosomal recessive disorder, whereas the remaining 3 are
autosomal dominant traits. For more information on the
genotype-phenotype correlation in patients with AIP, see
the report by von und zu Fraunberg et al64 in this same issue.
In all 4, the acute attack is associated with elevations of
the porphyrin precursors ALA and porphobilinogen (PBG).
Elevated concentrations of these precursors may be mea-
sured in urine and are used to diagnose the acute attack21.
Although ALA or PBG may themselves be neurotoxic and
therefore responsible for the symptoms of the acute attack,
this has never been established with certainty, and others
have hypothesized that the acute attack may result indi-
rectly from heme deficiency42. In both ALA dehydratase
deficiency porphyria and AIP, the enzyme defect occurs
proximal to the first porphyrin in the heme synthetic path-
way: hence porphyrins (as opposed to their precursors) do
not accumulate, and photosensitivity is not a feature.
The acute attack is a potentially fatal condition char-
acterized by severe abdominal pain, autonomic dysfunction,
and a motor neuropathy that may progress to quadriparesis21.
It is associated with hyperinduction of the heme synthetic
pathway41,42. The cardinal clinical features are an auto-
nomic neuropathy typically presenting as severe abdominal
pain, nausea, ileus, hypertension, and tachycardia, which
may progress over several days to a motor neuropathy and
eventually a profound flaccid quadriparesis21. Other features
that have been described include confusion, seizures, and
psychosis.
The acute attack may be precipitated by a number
of factors having in common the potential to induce heme
synthesis. This includes exposure to many drugs43. Other
factors that have been implicated include the menstrual
cycle, infection, starvation, and stress21.
Therapy for the acute attack consists of symp-
tomatic treatment—particularly opiate analgesics—and spe-
cific therapy designed to reduce the rate of porphyrin
synthesis29,41,42. The earliest such treatment was carbohy-
drate loading19, which was shown to have a suppressant
effect on porphyrin synthesis. Hematin was subsequently
introduced into clinical practice6. This is a reduced form of
heme which is highly effective in inhibiting porphyrin syn-
thesis via a negative-feedback inhibition of the rate-limiting
enzyme of the heme synthetic pathway, ALA synthase. In
many parts of the world, heme is now administered as heme
arginate, which has greater stability and an improved side
effect profile50,58. The formulation was not yet registered in
the United States at the time of this writing.
Both ALA dehydratase deficiency porphyria and he-
reditary coproporphyria are rare, whereas AIP and VP are
more commonly encountered. AIP is associated with a de-
fect in the enzyme porphobilinogen deaminase. It may be
diagnosed biochemically by demonstrating elevated uri-
nary concentrations of ALA and PBG in the absence of the
characteristic porphyrin elevation typical of the other he-
patic porphyrias; by demonstration of a reduced PBG de-
aminase activity on kinetic assay; or by demonstration of a
disease-specific mutation in the PBG deaminase gene24.
VP is associated with a defect in the enzyme protoporphyrin-
ogen oxidase, the penultimate enzyme in the heme synthetic
pathway 29. It may be diagnosed biochemically by demon-
strating a characteristic plasma fluorescence peak at 625
nm; by demonstrating a characteristic pattern of porphyrin
accumulation in the stool (principally protoporphyrin and
coproporphyrin); or by demonstrating reduced activity in
the protoporphyrinogen oxidase enzyme or a disease-specific
mutation in the corresponding gene27. The prevalence of AIP
and VP in Europe is estimated at 1.5 per 100,000 and 0.5 per
100,000, respectively21. In South Africa, VP is extraordi-
narily common, the result of a founder mutation introduced
from the Netherlands in 1688, and is estimated to have a
prevalence of 3 per 1000 in the white population14.
Because the porphyrias are uncommon, few centers
will accumulate a large experience with the management of
the acute attack, and because of the small number of patients
with these disorders, we cannot easily design randomized
controlled trials of therapy. Indeed, the definitive case series
date back to 198020,47,49, although 2 more recent papers
have reported experience with the acute attack of AIP in
Argentina16 and Chile45. In this paper we report our expe-
rience with 112 sequential acute attacks in patients admitted
to our hospital. Our experience is unusual in that we have
treated substantial numbers of attacks associated with both
AIP and VP. We have compared the 2 disorders and have
identified some important differences. We include details
on individual patients who have deviated from the usual
course of the acute attack in terms of symptoms, course,
or response to therapy. We believe that our experience will
assist physicians called upon to treat patients with the acute
attack of porphyria.
PATIENTS AND METHODS
All patients admitted to Groote Schuur Hospital, the
principal teaching hospital of the University of Cape Town,
Cape Town, South Africa, with a diagnosis of the acute
attack over a 14-year period were admitted and treated
under the direct supervision of 1 of us (RH). A diagnosis of
the acute attack was based on the following criteria: proven
porphyria, severe abdominal pain in the absence of sig-
nificant abdominal tenderness, absence of any other cause
for the symptoms, and demonstration of elevated urine ALA
and PBG concentrations.
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In all cases AIP and VP were confirmed by precursor
and porphyrin measurement in urine, stool, and plasma using
standard diagnostic criteria24,27. The relative frequency of
the acute attack was compared with the relative frequency
with which new patients with AIP and VP were identified
in our diagnostic laboratory, which serves as the reference
laboratory for porphyria in South Africa, using the same
criteria.
The following details were recorded for every admis-
sion: possible precipitating factors, presenting symptoms,
physical findings, urine ALA and PBG, and serum sodium,
potassium, urea, and creatinine concentrations. Patients were
examined twice daily. All complications were documented.
Pulse and blood pressure were monitored and recorded.
Electrolyte estimations were repeated in patients who failed
to improve rapidly or in whom initial values had been
abnormal. A record was kept of all drugs administered.
It is frequently difficult to ascribe the acute attack to
a specific precipitating event: even when an association is
present it may not be causal. For the purposes of this study,
we implicated a drug if the acute attack had arisen within
7 days of commencement of exposure to drugs known to be
porphyrinogenic. We reported menstrual precipitation only
where repeated, stereotypic acute attacks arose during the
late luteal phase of the menstrual cycle. We reported an
associated infection if the acute attack had arisen within
4 days of the first presentation with infection.
Changes in the severity of symptoms were assessed
by 2 methods. First, the total dose of meperidine (pethidine)
administered each day was recorded. In the few instances
where other opiates such as morphine or fentanyl were ad-
ministered, the dose was converted to the equivalent dose
of meperidine thus: 100 mg fentanyl = 10 mg morphine =
100 mg meperidine. Second, a symptom severity score was
applied for each day of the admission, based on a reading
of the clinical notes for that particular day. This was made
without reference to the meperidine requirements. Pain was
scored as follows: 2 = severe pain, 1 = moderately severe
pain or pain that had clearly lessened in intensity, 0 =
substantially pain free.
Statistical Analysis
All data were entered into a Microsoft Access data-
base. Data were analyzed using Microsoft Access (Microsoft
Office XP, Microsoft, Seattle), and statistical comparisons
were performed with Statistica (Statistica 6.1, StatSoft Inc,
Tulsa) or MedCalc (MedCalc version 7.2.0.0, MedCalc
Software, Mariakerke, Belgium) software. Where data were
normally distributed (urine ALA and PBG, serum electro-
lytes, heart rate, and blood pressure), comparisons were
made with the Student t-test; otherwise the Mann-Whitney U
test was employed. 2  2 tables were analyzed by the Fisher
exact test. Sequential data were analyzed by ANOVA, and
posthoc analysis was performed with the Tukey honest
significant difference. Attack-free survival following the first
attack was determined by the Kaplan-Meier method, and
differences in attack-free survival between AIP and VP were
calculated by Gehan’s Wilcoxon test.
RESULTS
Twenty-five patients were admitted and treated for
the acute attack during the study period; 15 with AIP (13
women, 2 men) and 10 with VP (5 women, 5 men). During
the same period we identified 687 new patients with a diag-
nosis of VP and 48 with AIP: these are patients referred for
testing as consequence of photosensitivity, abdominal pain,
or a family history of porphyria. The relative risk for the
acute attack for patients with AIP versus VP is therefore
14.3 (confidence interval, 6.3–32.7, p < 0.00001). Many of
the patients experienced more than 1 attack, and we thus
report our experience with 112 attacks. This represents all
acute attacks seen by us with the exception of 2 patients
who demonstrated a severe course of near-continuous acute
attacks without typical periods of remission between attacks.
Inclusion of these data would strongly bias our results
towards these 2 unusually severe patients. Data relating to
the earlier part of the second patient’s course, when the
attacks were more typical and she was able to return home
in periods of remission, have been included.
Our experience is summarized in Table 1. Additional
patient information is given in Table 2. Approximately half
the patients had repeated attacks. The female:male ratio
was significantly higher in AIP than VP (p < 0.0001).
The median age at the first attack for AIP (23.5 yr) is
significantly lower than that for VP (30 yr) (p < 0.0001).
Although repeated attacks appeared more common in
AIP than VP, there was no significant difference in the pro-
portion of patients experiencing single rather than multiple
attacks (p = 0.70), nor in the median number of attacks per
patient (p = 0.5). However, Kaplan-Meier survival analysis
shows a tendency for AIP patients to have an earlier relapse
than those with VP (Figure 1), although the difference does
not reach statistical significance (p = 0.17).
Precipitating Factors
Drugs known to be dangerous in porphyria were im-
plicated in 16 of 25 attacks in VP (64%), and in 11 of 87
attacks in AIP (10%). Attacks clearly related to the men-
strual cycle were documented in 35 of 69 attacks in women
with AIP (51%) and may possibly have contributed to
the 30/69 attacks for which no clear cause was evident
(43.5%); in contrast, there was not a single episode
of menstrually related porphyria in women with VP.
AIP is therefore highly significantly associated with men-
strual attacks, and drug exposure with VP (p < 0.00001).
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Uncommon precipitants were pregnancy (1 attack) and
infection (2 attacks).
The following drugs were implicated: alcohol and
cannabis in combination (9 instances), combined oral
contraceptive pill or progesterone (3 instances), erythromy-
cin (1 instance), rifampicin or rifampicin/INH/pyrazinamide
combination (2 instances), nonsteroidal antiinflammatory
(type unknown, 1 instance), and phenytoin (1 instance).
Particularly striking were the drugs of abuse, alcohol and
cannabis, which may frequently be taken in combination.
Indeed, these were responsible for most of the recurrent
attacks in males.
Presenting Symptoms and Signs
The median duration of symptoms before admission
for both AIP and VP was 2 days (range, 0–18 d). Clinical
features are shown in Table 3. Tachycardia and hyperten-
sion were frequently not prominent at initial presentation,
but developed as the attack progressed: levels were highest
at a mean of 48 hours after admission. Both parameters
settled completely with remission of the attack, although
3 patients with AIP, all of whom had repeated episodes,
progressed subsequently to chronic hypertension requiring
therapy; this was associated in each case with chronic renal
impairment.
Unusual Presentations of the Acute Attack
Spontaneous Disappearance of Pain
Two patients, a 27-year-old woman and a 32-year-old
man, neither of whom was previously known to have
porphyria, were admitted to hospital with abdominal pain.
Both were shown to have VP: elevated urine PBG levels
confirmed that they were in an acute attack. Neither received
heme arginate initially. After approximately 36 hours, the
abdominal pain abruptly ceased. This was interpreted as
evidence of spontaneous improvement, yet in both cases,
disappearance of the pain was followed within approxi-
mately 6 hours by the rapid onset of a flaccid quadriparesis.
The first patient required a prolonged period of assisted
ventilation and prolonged recovery, whereas the second
patient was less severely affected.
Presentation with Predominant Psychosis
A 25-year-old woman with a family history of VP
presented to her physician with a sudden onset of confusion
and abnormal behavior. She had no history of abdominal
pain, and no objective neurologic abnormalities, and no
cause for the confusion could be found. Electrolytes were
normal. A brain computed tomography (CT) scan was
unremarkable. Stool and plasma porphyrin analysis con-
firmed VP. She recovered spontaneously within 7 days.
Mental state was entirely normal, although she had evi-
dence of a residual small-fiber neuropathy accompanied by
a mild glove-and-stocking sensory loss and hyperesthesia.
In this single patient, the acute attack had a predominantly
neuropsychiatric presentation, but our experience suggests
that this is a rare manifestation.
Adrenergic crisis
Although hypertension and tachycardia were frequent-
ly encountered in our patients, the presentation in 1 patient
known to have AIP was so extreme as to suggest a diagno-
sis of pheochromocytoma. She was admitted shortly after
undergoing uterine evacuation for an incomplete abortion
under general anesthesia. On admission, serum sodium was
130 mmol/L, systolic blood pressure 230 mm Hg, and dia-
stolic blood pressure 130 mm Hg; pulse rate was 144/min.
She appeared to have little or no abdominal pain, but was
drowsy and confused. A brain CT scan showed multiple
areas of attenuation in keeping with ischemia or infarction.
The serum sodium level declined to 120 mmol/L despite
adequate intravenous rehydration with normal saline, and
she developed seizures. The hypertension and tachycardia
failed to respond to high doses of combined alpha- and beta-
adrenergic blocking agents. We considered the possibility
of a coincidental pheochromocytoma. She was admitted to an
intensive care unit, intubated and ventilated, and treated with
intravenous magnesium sulfate, alpha- and beta- blockers,
TABLE 1. Average Number, Median Number, and Range of Discrete Attacks Classified by Sex and Diagnosis (Data pertaining to
the patient with continuous unremitting acute attacks are excluded)
Variegate Porphyria Acute Intermittent Porphyria All
Male Female Total Male Female Total Total
Patients (n) 5 5 10 2 12 14 24
Age at first attack (yr) 31 (24–36) 30 (27–34) 30 (24–36) 24 (22–27) 23.5 (20–36) 23.5 (20–36) 27 (20–36)
Attacks (n) 18 7 25 14 73 87 112
Patients experiencing single attack (n) 2 4 6 1 6 7 13
Patients experiencing recurrent attacks (n) 3 1 4 1 6 7 11
Median no. of attacks per patient (range) 2 (1–8) 1 (1–3) 1 (1–8) 7 (1–13) 2.5 (1–33) 2.5 (1–33) 1 (1–33)
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TABLE 2. Patient Characteristics
Patient Diagnosis Sex Ethnicity
Age
at First
Attack (yr)
No. of
Attacks Additional Information
1 AIP F Mixed 22 10 Menstrual attacks. Gonadal suppressive therapy not indicated in
view of relative infrequency of attacks.
2 AIP F Mixed 24 5 Menstrual attacks: has had subsequent further menstrual attacks
treated elsewhere and attacks during mid-pregnancy. Gonadal
suppressive therapy not indicated in view of relative infrequency
of attacks.
3 AIP M Mixed 22 13 Numerous attacks related to recreational drug use, died following
an untreated attack at another center.
4 AIP M Black 27 1 Single, uncomplicated attack.
5 AIP F Mixed 22 1 Severe attack with pronounced autonomic effects mimicking
pheochromocytoma. Cerebral ischemia that reversed following
heme arginate and magnesium sulfate.
6 AIP F Black 36 1 Single, uncomplicated attack.
7 AIP F Mixed 26 >100 Developed a pattern of continuous unremitting attacks poorly
responsive to heme arginate and tin protoporphyrin. No
response to gonadal suppressive therapy. Considered for liver
transplantation but condition was too poor to attempt this.
Eventually died in an unremitting attack. Data on individual
attacks not included in this series.
8 AIP F Mixed 20 1 Developed quadriparesis on first admission to another hospital,
before diagnosis. Required ventilation for 8 wk. Has had several
subsequent attacks treated in another center, which have
responded well to heme arginate.
9 AIP F Mixed 23 33 Numerous recurrent attacks. No response to gonadal suppressive
therapy. Received numerous courses of heme arginate and tin
protoporphyrin. Eventually died.
10 AIP F Black 29 1 Menstrual attack: has subsequently developed a problem of
recurrent menstrual attacks treated in another center but has not
responded to gonadal suppressive therapy.
11 AIP F Black 25 4 Prolonged course complicated by staphylococcal septicemia and
seizures during first admission. Subsequent attacks have
responded well to heme arginate.
12 AIP F Mixed 21 6 Menstrual attacks. Gonadal suppressive therapy not indicated in
view of relative infrequency of attacks.
13 AIP F White 28 8 Menstrual attacks with eventual complete response to gonadal
suppressive therapy.
14 AIP F White 34 1 Single, uncomplicated attack.
15 AIP F Mixed 20 1 Single, uncomplicated attack.
16 VP M White 24 8 Repeated attacks related to recreational drug use: no further
attacks following behavior modification.
17 VP F White 34 1 Single, uncomplicated attack.
18 VP M White 31 6 Repeated attacks related to recreational drug use: no further
attacks following behavior modification.
19 VP F Black 27 1 Single, uncomplicated attack.
20 VP F Mixed 27 1 Initial pain appeared to settle but was followed by quadriparesis.
Ventilated for 12 weeks: eventual recovery in 12 months.
21 VP M White 27 1 Single, uncomplicated attack.
22 VP F Mixed 30 1 Single, uncomplicated attack.
23 VP F Mixed 30 3 One attack during pregnancy.
24 VP M White 32 2 Uncomplicated attacks.
25 VP M Mixed 36 1 Abrupt cessation of pain was followed by the onset of moderate
neuropathy with full recovery.
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and heme arginate. This regimen was highly effective
in controlling both the adrenergic features and the seizures.
Recovery was rapid and she was discharged, neurologically
intact and completely asymptomatic, after 9 days. A repeat
CT scan was completely normal, and she remained well 4
years later.
Biochemical and Electrolyte Disturbances
ALA and PBG values were significantly higher in AIP
than in VP. Mean values were, for AIP and VP respectively,
as follows: for ALA, 386.1 (SD 226.5) and 189.1 (SD 115.7)
(p = 0.02); for PBG, 544.9 (SD 242.0) and 168.9 (SD 122.3)
(p = 0.02). Hyponatremia was common during the attack.
A sodium value below 135 mmol/L was recorded in 31.3%
of cases at some stage of the admission. Mean sodium levels
did not differ between AIP and VP. Severe hyponatremia
(Na < 125 mmol/L) was noted in 5 admissions: 3 of these
admissions were complicated by seizures, and 4 were com-
plicated by neuropathy. The lowest sodium values noted
were 100 and 104 mmol/L. In all 5 cases of severe
hyponatremia, urine sodium concentrations were found to
be markedly increased. The serum sodium failed to improve
in response to fluid restriction alone, and rose only after the
infusion of hypertonic saline. In 2 instances, urinary sodium
loss was accompanied by marked kaliuresis and calciuresis,
suggesting a primary tubular defect.
The mean urea and creatinine concentrations on ad-
mission were 8.0 (SD 2.9) and 114.6 (29.8), respectively;
urea levels were elevated in 52.7% and creatinine values, in
46.4% at some stage of the admission. This may represent,
in part, dehydration, since values typically improved rapidly
following admission and intravenous fluid administration.
No consistent changes in potassium, calcium, or magnesium
levels were noted.
Therapy
Opiates were required in 98% of cases; the total
meperidine dose required varied from 50 mg to more than
10,000 mg per admission, with a median dose of 1200 mg
per admission. All patients received intravenous normal
saline-dextrose for at least 48 hours following admission.
Beta-blockers were prescribed in 35% of admissions (AIP,
43%; VP, 8%; p = 0.002). Antiemetics were administered
in 54% of admissions (AIP, 51%; VP, 68%; p = 0.35).
Heme arginate was used in 75 admissions (67%). A
standard dose of 125 mg, irrespective of body mass, was
used: this is an empirically chosen dose, convenient in that
it represents a 5-mL aliquot from a 10-mL ampoule, which
we have found effective in practise. The number of doses
required to abort the attack varied: 5 doses: 5 (7%), 4 doses:
40 (53%), 3 doses: 23 (31%), 2 doses: 8 (11%). Four attacks,
all in patients with AIP, required a second course of heme
arginate following an inadequate response to the first course.
Infusion of heme arginate was complicated by phlebitis at
the site of infusion in 14 of 79 instances, all occurring early
in this series when heme arginate was administered in saline.
Heme arginate was later administered in suspension with
20% human serum albumin, and no further cases of phlebitis
were observed.
The median time from admission to commencement
of heme arginate was 24 hours (range, 2 h to 12 d). In many
instances, initiation of heme therapy was delayed, either
to assess whether symptoms would settle on conservative
measures alone, or because of delays in obtaining the med-
ication from suppliers. This gave rise to an unplanned ex-
periment that has allowed us to make some assessment of
TABLE 3. Presenting Symptoms and Signs in 112 Acute
Attacks
No. (%)
Pain 109 (97.3)
Nausea and vomiting 88 (78.6)
Hypertension (systolic bp > 130) 83 (74.1)
Tachycardia (heart rate > 100) 42 (37.5)
Hyponatremia (sodium < 135 mmol/L) 35 (31.3)
Constipation 30 (26.8)
Psychosis 1 (0.9)
FIGURE 1. Kaplan-Meier survival curve, dated from the time
of discharge after the first admission for an acute attack. The
horizontal axis represents the interval in months from the date
of discharge after the first attack before admission for a sec-
ond and subsequent attack. Patients with acute intermittent
porphyria are represented by the solid line, and patients with
variegate porphyria, by the dashed line. The difference in the 2
curves is not significant (p = 0.17).
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the efficacy of heme arginate. Figures 2 and 3 show the
symptom severity score and the meperidine requirement by
treatment day, ranging from Day 6 pretreatment (Treatment
Day 6) to Day 8 after initiation of heme therapy (Treatment
Day +8). We note that heme therapy had an early beneficial
effect on both the severity of the attack and the requirement
for meperidine, both of which decreased promptly once
heme arginate was administered. The decline in both severity
score and meperidine requirement is highly significant (p <
0.0001). Posthoc analysis recorded a significant deterioration
in symptoms in the days preceding initiation of therapy as
reflected by analgesic requirement, followed by a highly
significant improvement after initiation of treatment with a
lag phase of 24–48 hours.
Course and Complications
The median time from admission to resolution of
symptoms was 6 days (range, 1–19 d). The median length
of hospital stay was 7 days (range, 1–56 d). Three pa-
tients remained longer than 30 days: 1 developed profound
quadriparesis requiring ventilation; a second developed
moderate paralysis complicated by staphylococcal septice-
mia requiring prolonged intravenous therapy; and a third
needed treatment of unrelated medical problems. This ex-
cludes the 2 patients described above who eventually became
hospital-bound.
Eleven of the 24 patients, 8 with AIP (57%) and 3
with VP (30%), demonstrated neuropathy. The neuropathy
developed before admission to our hospital, usually under
the care of another hospital, in all subjects except 2. In most
cases the neuropathy had therefore developed before por-
phyria had been diagnosed, and in only 2 of 112 admissions
did neuropathy supervene during the course of admission to
our hospital. Neither patient had received heme arginate.
Neuropathy was in most cases limited to mild weak-
ness of the extremities manifesting as wrist-drop and foot-
drop. We encountered 3 patients with quadriparesis, 2 of
whom developed this complication during their initial attack
elsewhere, and who were diagnosed as having porphyria
only after the development of quadriparesis. The third be-
came quadriparetic while under our care. All 3 improved
with physiotherapy and orthopedic supports and eventually
regained the ability to walk. The frequency of neuropathy
and seizures did not differ between patients with AIP and
those with VP.
We noticed an interesting phenomenon among our
patients with preexisting neuropathy and recurrent attacks.
Shortly after the start of a new attack, a rapid diminution
in distal motor power was frequently demonstrable. When
heme arginate was administered, there was a prompt return
to the status quo ante.
Three patients with neuropathy had a striking clinical
picture apparently resulting from a small-fiber neuropathy.
They reported severe pain and discomfort in response to
trivial stimuli over the whole body, such as intense dis-
comfort resulting from tight underwear or even a fold in
the bed sheets. In 1 of these patients the complaints were
FIGURE 3. Effect of heme therapy on meperidine require-
ment. Treatment was commenced on Day 0. Analgesic re-
quirement was maximal on the day following the first dose of
heme. Values on Days 3–9 are significantly lower as shown.
Values on Days 3, 2, and 1 are also significantly lower,
indicating an increasing severity of symptoms before heme
arginate was commenced. The arrows refer to the respective p
values with respect to Day 1 as returned by posthoc analysis.
FIGURE 2. Effect of heme therapy on symptom severity
score. Treatment was commenced on Day 0. Symptoms were
maximal on Day 0. Values on Days 2–9 are significantly lower
as shown. The arrows refer to the respective p values with
respect to Day 0 as returned by posthoc analysis.
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wrongly ascribed to repeated acute attacks, and she received
repeated doses of meperidine and heme arginate inappropri-
ately. With adequate explanation, reassurance, and simple
analgesics, she required no further opiates, and her condi-
tion improved over several months. One patient had striking
peripheral features of autonomic nerve dysfunction: light
stroking of the dorsal surface of the forearm would bring
about dramatic piloerection and profuse sweating in that arm.
We conclude that in some patients, acute attacks may result
in a complex regional pain syndrome that should not be
mistaken for evidence of ongoing acute attacks.
Seizures were encountered in 6 attacks (5 AIP, 1 VP).
Three of these were associated with hyponatremia. One was
associated with a prolonged acute attack complicated by
systemic staphylococcal septicemia. Two other episodes, in
a single patient with severe AIP, were related to the use
of large doses of meperidine; 1975 mg total dose in 1 attack,
and 10,650 mg total dose in the second, and were preceded
for several hours by myoclonic jerks. Both the seizures and
the myoclonus were easily abolished by clonazepam.
Three patients died, all with AIP. Two required per-
manent admission for unrelenting symptoms of the acute
attack. Prophylactic administration of heme arginate in the
interval between attacks, parenteral GnRH agonist therapy,
and a subcutaneous implant of testosterone53 were ineffec-
tive. Both patients demonstrated a pattern of severe, unre-
mitting attacks such that courses of heme arginate were
required at intervals of 7–10 days; with time, a progres-
sively poorer response to heme arginate was observed. We
developed a protocol whereby the heme oxygenase inhibi-
tor tin protoporphyrin in a dose of 25 mg was injected
intravenously for 3 daily doses at the start of every second
course of heme arginate. Tin protoporphyrin was given
simultaneously with heme arginate and was well tolerated
other than for photosensitivity, which was not a problem
provided the patients avoided direct sunlight. This appeared
to augment the symptomatic relief afforded by heme
arginate, but in both patients the course was one of
inexorable decline and finally death. The third patient, a
22-year-old man admitted on 13 occasions over 25 months
with acute attacks, most of which appeared to follow alcohol
and cannabis abuse, subsequently died following an acute
attack in another city; he had not received heme arginate
during that admission, although this would appear to have
been indicated.
Contrasting Severity of AIP and VP
Some markers of severity of the acute attack are sum-
marized in Table 4. Blood pressure, pulse rate, and heme
arginate requirement were significantly higher in patients
with AIP than in patients with VP. No significant difference
could be shown, however, in the length of admission, the
time to resolution, or the meperidine requirement.
DISCUSSION
Incidence and Severity of Acute Attacks
Our study clearly suggests an increased risk of acute
attacks in patients with AIP compared with those with VP.
Although VP was diagnosed nearly 15 times more often
than AIP in our population, the ratio of patients with VP
with acute attacks to those with AIP was 1:1.4, indicating a
14-fold increase in risk. Furthermore, the patient profile is
dissimilar in that our patients with AIP were predominantly
young women, whereas patients with VP were, on average,
7 years older, with an equal sex-ratio. Thus, while we have
confirmed the greater susceptibility of women to acute at-
tacks reported for AIP elsewhere16,45, this would not appear
to be true of VP. Furthermore, the small number of patients
we observed with acute attacks of VP suggests that the
acute attack itself is currently a rare manifestation of VP.
This conclusion is supported by our own work on the clini-
cal expression of VP, where we found that, in contrast to
the 40% of adults with VP who exhibit skin disease, acute
symptoms were uncommon28.
Recurrent attacks are a significant feature in some
patients. Kauppinen and Mustajoki33 have emphasized that
recurrent acute attacks are less common where porphyria is
TABLE 4. Relative Severity of the Acute Attack: Parameters Observed in Attacks Associated With AIP and VP
Acute Intermittent Porphyria Variegate Porphyria
Mean SD n Mean SD n p
Maximal systolic bp (torr) 156.5 22.00 83 145.7 20.63 23 0.036
Maximal diastolic bp (torr) 98.2 16.09 83 86.7 14.74 23 0.002
Maximal pulse rate 93.3 14.18 83 85.2 12.75 23 0.015
Doses of heme arginate 3.9 1.14 69 2.7 0.90 11 0.002
Total meperidine requirement (mg) 1746 1620 83 1278 1053 20 0.22
Length of admission (days) 8.3 6.8 87 8.0 9.4 25 0.89
Interval before improvement (days) 6.3 3.3 85 5.4 3.7 25 0.21
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diagnosed in asymptomatic patients, in contrast with those
diagnosed during an established attack. In a series reported
in 199916, 81% of symptomatic patients with AIP developed
recurrent attacks. Although we observed a lower propor-
tion of recurrent attacks in patients with VP than in pa-
tients with AIP, the difference was not significant. This may
relate to our observation that most recurrent attacks in
VP were associated with drug ingestion and were therefore
preventable, whereas the same association was not observed
in AIP.
Precipitating Factors
In patients with VP, acute attacks were strongly asso-
ciated with medication, whereas acute attacks in patients
with AIP were more likely to be associated with the men-
strual cycle or with an unproven etiology. Despite the high
prevalence of porphyria in our population, precipitation of
the acute attack by drugs appears to be rare. To our surprise,
the drugs most commonly implicated in precipitating the
acute attack were the recreational drugs alcohol and can-
nabis. Such exposure was frequently associated with re-
current episodes. In 2 subjects in whom we noted this
association, all further attacks ceased once they desisted
from exposure to these agents. The third subject subse-
quently died following an attack in another city. The effect
of cannabis on heme synthesis has not been reported,
whereas several authors have discussed the effects of alco-
hol on porphyrin metabolism38,44,52. Although alcohol in
moderation is probably safe, there is evidence that alcoholic
binges may be associated with acute attacks33,59.
A striking feature is the number of women with AIP
in whom attacks appear to have been menstrually related.
Indeed, the number may be higher than we report, since it is
possible that hormonal effects may have contributed to
some of the attacks in women for which no definite cause
could be ascribed. Our definition of a menstrually related
attack was restrictive in that we described as menstrually
related only attacks that were recurrent, with a clear onset
of symptoms in the late-luteal phase of the cycle. Yet we
were unable to link a single attack in women with VP
with the menstrual cycle, suggesting that this association
is a very uncommon feature of VP. We treated 3 patients
with AIP and apparent menstrually induced exacerbations
with gonadotrophin-releasing hormone agonists1. Only 1
responded with a complete remission, whereas the other 2
patients continued to experience monthly attacks despite
amenorrhea and documented hormonal suppression. Such
an unpredictable response has been reported by others26.
Certain factors commonly stated to aggravate porphyr-
ia were notably absent in our series. In the Argentinean
series16, 20% of attacks were ascribed to infections and
30% to starvation. Neither of these played a significant role
in our series. We recorded a single attack associated with
pregnancy. Subsequent to the termination of the present
study, 1 of our patients, who had revealed a pattern of
menstrual attacks (Patient 2) became pregnant and experi-
enced acute attacks in the late second trimester; we will
report our experience with her management in the future.
With this exception, we are unaware of any attacks in preg-
nancy occurring in South Africa during the past 15 years. It
is clear that early reports, which suggested that approxi-
mately 50% of women with the acute porphyrias would
develop a complicating acute attack in pregnancy9,30, over-
stated the risk. A 1992 report from Finland33 reported a rate
of 8% in patients with porphyria followed prospectively,
whereas our observed rate is very low indeed.
Clinical Features
The cardinal features of the acute attack have not
changed since those described in previous series, with ab-
dominal pain being nearly universal16,20,47. Although pain is
the most common presenting feature, clinicians should be
aware that exceptional patients will present atypically. Thus
we have learned that the sudden cessation of abdominal pain
may not indicate improvement, but may provide warning
of incipient quadriparesis. Pain was not prominent in 2 of
our patients, which led us to withhold heme arginate with
unfortunate consequences. Pain was not noted at all in a
third, who presented with psychosis alone. Presentation
without pain is therefore highly atypical and may lead to a
delay in starting therapy2.
Hypertension is common during the attack. Antihy-
pertensive therapy with beta-blockers was used in approx-
imately half the admissions, overwhelmingly in patients with
AIP. However, we have learned that in most cases, both
blood pressure and pulse rate will subside spontaneously as
the attack improves, and there is little need for specific
antihypertensive therapy in the early phase of the attack. In
only 1 instance was the hypertension sufficiently severe to
warrant treatment in its own right. An association between
AIP, chronic hypertension, and chronic renal failure, pos-
sibly related to protracted vasospasm, has been shown3.
Three of our patients with AIP, all of whom have had
repeated episodes, appear to illustrate this.
We identified 1 attack in which the presentation was
predominantly of an acute psychosis without the classic fea-
tures of the acute attack. Similar cases have been reported56,
but this must be regarded as an exceptional and extremely
rare mode of presentation, which probably has been over-
stated in general reviews of porphyria. It is notable, too, that
the psychosis regressed completely with recovery from the
acute attack.
Hyponatremia is a common manifestation of the acute
attack that deserves more attention than it is usually given.
About one-third of the attacks in the current series were
accompanied by hyponatremia; Morales Ortega et al45
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encountered hyponatremia in 53% of the acute attacks they
described. Severe hyponatremia is dangerous and is a mark-
er of a particularly severe attack. Of 5 admissions marked
by severe hyponatremia, 4 were complicated by neuropathy,
whereas the fifth demonstrated a severe course marked by
profound adrenergic activity. Hyponatremia may be due in
part to dehydration, although other factors may be operative,
as suggested by Eales et al20. In the 5 patients we describe
with severe hyponatremia, the biochemical findings were
more in keeping with a primary tubular defect with salt-
wasting, as previously suggested53, than with the syndrome
of inappropriate ADH62. We therefore recommend that
severe hyponatremia be treated with hypertonic saline from
the beginning, rather than fluid restriction. Hyponatremia
must be corrected slowly and cautiously since rapid
correction of hyponatremia in patients with AIP has resulted
in central pontine myelinolysis and cortical laminar necro-
sis55. Furthermore, intravenous hypotonic dextrose solutions
should be avoided in the acute attack in view of the risk
of aggravating hyponatremia. We recommend the use of
intravenous normal saline. Carbohydrates may be given
orally if tolerated, or as a saline-dextrose solution. Our ex-
perience has shown that heme arginate is so effective in
terminating the attack that additional carbohydrate loading
is not necessary. Serum sodium levels should be checked
frequently in patients with more severe forms of the acute
attack.
Several lines of evidence suggest that the average
severity of the acute attack in the current series was worse in
patients with AIP than in those with VP. The mean systolic
and diastolic blood pressures, pulse rate, and the proportion
of patients requiring heme arginate were all significantly
higher in AIP than in VP. We noted a trend to higher anal-
gesic requirements, length of hospital stay, and duration of
symptoms, although these did not reach statistical signifi-
cance. However, the overall incidence of significant com-
plications, such as seizures and neuropathy, is similar, and
it is clear that a fully developed acute attack poses the
same risk to the patient with VP as it does to the patient
with AIP.
Complications
The incidence of severe complications of the attack is
markedly lower in the current series than in those described
by Eales et al20 and Mustajoki47. Neuropathy was a rare
occurrence in patients primarily admitted and managed by
us, and it is notable that in the 2 patients seen by us who
developed severe neuropathy, heme arginate had not been
given. In both instances this was because we had been
misled by the absence of ongoing pain into believing that
the attack had settled. In most instances, neuropathy was
mild and was limited to wrist- and foot-drop. This confirms
the trend toward an increasingly favorable outcome for the
acute attack noted in more recent reports5,32,33. During this
time, several factors have changed that may have led to a
better outcome. There is a greater awareness and under-
standing of porphyria among both doctors and patients.
Diagnostic tests for porphyria and for the acute attack have
become more reliable and accessible. Patients understand
their illness better and are perhaps more likely to present
to hospital early. Management protocols for the acute crisis
have been refined, and specific therapy, heme arginate, is
now available.
Our experience in patients with preexisting neuropathy
and recurrent attacks suggests that these patients operate just
below a threshold of clinically evident nerve damage: any
subsequent acute attack results in immediate deterioration
in nerve function, which is reversible provided that heme
arginate is infused promptly. In light of this observation, it
is our standard practise to ensure that every patient with a
history of previous neuropathy receives heme arginate with-
out delay, whereas other patients are allowed 24 hours to
determine whether spontaneous remission will occur.
A 1996 study10 reported that 10 of 268 (3.7%) Swedish
patients with porphyria had experienced seizures; in 6 pa-
tients, these were associated with an acute attack of AIP, and
3 patients had been severely hyponatremic. Seizures were
rare in our patients. In 3 cases, seizures accompanied severe
hyponatremia, an association noted previously18,62. In 2
further instances, we ascribed the seizures to the use of high
doses of meperidine. Meperidine is metabolized to norme-
peridine, a metabolite that is epileptogenic40, and meperi-
dine-related seizures have been reported in a patient with
hereditary coproporphyria15. Seizures relating to meperidine
should be suspected in any patient receiving high doses in
whom myoclonic jerks are noted. We have found clonaze-
pam to be a safe and effective agent, for both the prevention
and the termination of seizures. We conclude that in most
instances, seizures during the acute attack are associated with
an identifiable precipitating cause.
We encountered 1 patient who manifested a severe
adrenergic crisis. Acute hypertension mimicking pheochro-
mocytoma as the main presenting feature of AIP has been
reported18,54. In our patient, intravenous magnesium sul-
fate57 was highly effective in controlling the autonomic
features, and we now recommend its use, along with heme
arginate and beta-blockade, in any patient in whom adren-
ergic or cerebral features dominate the presentation. This
patient demonstrated reversible neurologic deficits and
neuroradiologic defects, presumably related to cerebral
vasospasm and ischemia. Both reversible and irreversible
findings have been described in case reports4,11,34,36,37,63.
Mortality
Of the patients described by De Siervi et al16 and
Morales Ortega et al45, approximately 15% died during an
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acute attack. Most of these deaths resulted from respiratory
failure, usually during the first attack, implying that the
diagnosis was made too late for effective suppressive
therapy. Certainly our results support the belief that the
prognosis of the acute attack has improved greatly over the
past 20 years31,33. None of our patients died during a
‘‘routine’’ acute attack, but rather after a protracted and
difficult course of repeated acute attacks, in 1 instance
totaling more than 100 consecutive attacks.
Treatment
Heme Arginate
The beneficial effect of exogenous heme in porphyria
is mediated via a repression of ALAS by a process of
negative feedback. Since the first reported use of hematin
in acute porphyria6, numerous reports have attested to its
efficacy in aborting the acute attack. Heme arginate was
introduced subsequently, and has greater stability and lower
incidence of complications49. Heme arginate is effective
in rapidly reducing ALA and PBG levels in the acute
attack21,29,35; this biochemical improvement is typically
followed within 48 hours by evidence of clinical resolution.
Neuropathy, once established, is not necessarily reversed by
the administration of heme48,51, which should therefore be
administered before neuropathy develops. The only con-
trolled trial of heme arginate25 was unable to show a
significant difference in outcome, although it suggested an
improvement in symptoms following treatment. Our expe-
rience, reflected in Figures 2 and 3, supports the hypothe-
sis that heme arginate is responsible for a rapid and reliable
improvement in symptoms. Furthermore, none of our pa-
tients developed serious complications such as hyponatre-
mia, neuropathy, or seizures once heme arginate had been
initiated; we have no doubt that it represents highly effective
therapy for the acute attack.
Typically the effect is short lived, and ALA, PBG, and
porphyrin levels begin rising within 48 hours of the last of
a four-day course of injections25,60. Thus the role of heme
arginate is to abort a crisis rather than as a prophylactic
measure in patients with porphyria. Since heme is known
to induce the enzyme heme oxygenase and thus to mediate
its own catabolism, tolerance would appear a reasonable
assumption. In 2 of our patients, prolonged, repeated use
of heme arginate led to an apparent decrease in efficacy,
suggestive of tolerance. This led us to combine the heme
oxygenase inhibitor tin protoporphyrin with the heme
arginate, with some apparent benefit.
Despite the suggestion that heme arginate infusion
is associated with a lower rate of thrombophlebitis than
hematin50,58,61, we frequently recorded severe thrombophle-
bitis at the infusion site when heme arginate was given in
saline, whereas administration in 20% human serum albumin
appeared to prevent this. We have not encountered renal
failure17, coagulopathy46, or anaphylaxis13 in association
with heme arginate.
Heme arginate is expensive. The current price in
the United Kingdom for 4 250-mL ampoules is [£]4500
(approximately 8200 United States dollars)8. We have been
able to reduce the cost to our service by using a standard
dose of 125 mg per patient irrespective of body weight. Nor
do we consider it necessary to treat every acute attack with
heme arginate. In our series, approximately 30% of attacks
responded to conservative measures alone. We have refined
our indications for initiation of heme arginate therapy as
follows. Treatment is begun immediately in any patient
with severe symptoms who shows evidence of incipient
complications such as neuropathy, hyponatremia, or sei-
zures; in patients with recurrent attacks who have required
heme arginate previously; and in any patient with evidence
of residual neuropathy from a previous attack. In other
patients, particularly those with VP, we treat expectantly for
the first 24 hours. If there is no improvement, we begin heme
arginate after 24 hours; since our experience has suggested
that rapid spontaneous resolution is unlikely in those who fail
to improve within this period.
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